VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 01, 2007) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that Dr. Bin Huang, Vice President of Corporate Development will be presenting at the BioContact Annual Conference in Quebec City, Canada on Thursday, October 4th, 2007. Dr. Huang will provide an overview of the Company and the Company’s two lead drug candidates, CTCE-9908 for the treatment of cancer and CTCE-0214 for neutrophil mobilization both in human clinical trials.